



CytoTools AG: DermaTools Biotech GmbH reports on further positive project developments for DermaPro®

- Market launch preparations in India are in full swing
- Centaur plans market launch for beginning of 2nd quarter 2020
- The European Medicines Agency (EMA) approves phase III trial planning
- DermaTools receives fresh capital thus safeguarding further working projects

Darmstadt, 21st January 2020 – DermaTools Biotech GmbH, the CytoTools AG subsidiary, reports today on further milestones achieved by its license partner Centaur Pharmaceuticals within the scope of the preparations for the market launch in India. The responsible authorities have, in the meantime, approved the final sales packaging. Therefore, the production and the final packaging of the medicine in the retail sales package can now be carried out. Furthermore, Centaur is currently implementing further production lines. According to the planning at present, Centaur will carry out the final market launch at the beginning of the 2nd quarter 2020. In the coming weeks, in preparation for this, symposiums will be held with leading expert physicians, emphasizing the importance of the launch of our innovative product Woxheal (this is the Indian trading name) for the treatment of diabetic foot wounds.

In addition to this, we can report on the positive results of the consultation procedures at the EMA (European Medicines Agency). With regard to the planned trial design of the phase III study in the diabetic foot syndrome indication, the European authorities have agreed to the proposed trial design and the associated data acquisition, therefore the submission of the required documents could now be completed. After translation into the required languages, and safeguarding the financing in the first quarter of 2020, the start of the European phase III trial can be implemented. In order to carry out the required steps until the trial begins, the financial prerequisites were fulfilled by DermaTools Biotech GmbH due to a small cash capital increase at the end of 2019 for the sum of about 0.5 million EUR.

Corporate News



CytoTools

This information contains specific future oriented statements. These reflect the opinion of CytoTools on the date of this release. The actual results achieved by CytoTools could substantially deviate from the future-oriented statements made. CytoTools is not obligated to update these future-oriented statements.

Contact:

CytoTools AG
Dr. Mark Andre Freyberg
Vorstand
Klappacher Str. 126
D-64285 Darmstadt
Tel.: +49-6151-95158-12
Fax: +49-6151-95158-13
E-Mail: freyberg@cytotools.de

UBJ. GmbH
Ingo Janssen
Haus der Wirtschaft
Kapstadtring 10
D-22297 Hamburg
Tel.: +49-40-6378-5410
Fax: +49-40 6378-5423
E-Mail: ir@ubj.de

About CytoTools

CytoTools AG is a German biotechnology company focused on translating fundamental biology research on the mechanisms of cell growth and programmed cell death into unique therapies that are designed to treat the cause of the disease rather than the symptoms. The Company has itself developed a robust and diverse pipeline of disease modifying therapies that comprise proprietary small molecules and biologics. These have the potential to provide new treatment options in dermatology, cardiology, angiology, urology and oncology. CytoTools AG is structured as an investment and holding company and as such holds investments in its subsidiaries DermaTools Biotech GmbH (62%) and CytoPharma GmbH (50%).